SEC Form 4 filed by Allena Pharmaceuticals, Inc.
$ALNA
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
NEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) ("Allena" or the "Company"), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to treat metabolic diseases, today reported completion of enrollment of the first two cohorts of its ALLN-346 Phase 2a Study 202 in gout patients with stage 2 (cohort A) and stage 3 (cohort B) chronic kidney disease (CKD). ALLN-346, which has received Fast Track Designation from the U.S. Food and Drug Administration (FDA), is a first-in-class, non-absorbed, orally administered enzyme in development for the tr
NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock. The Special Meeting will now be held on August 4, 2022, at 9:00 a.m., local time via live webcast. The new record date for the
NEWTON, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting, which was scheduled for July 5, 2022, to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock. The date of the rescheduled special meeting, and the new record date for determining the
4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)
4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)
4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)
SEC STAFF ACTION - Allena Pharmaceuticals, Inc. (0001624658) (Filer)
NT 10-Q - Allena Pharmaceuticals, Inc. (0001624658) (Filer)
25-NSE - Allena Pharmaceuticals, Inc. (0001624658) (Subject)
NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock. The Special Meeting will now be held on August 4, 2022, at 9:00 a.m., local time via live webcast. The new record date for the
- Versantis establishes wholly-owned U.S. subsidiary, Versantis, Inc. - - Current CEO, Vincent Forster, to maintain his key role as Chief Scientific Officer - Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, today announced the appointment of Mark J. Fitzpatrick as Chief Executive Officer (CEO) and member of the board of directors, effective January 1, 2022. He joins Versantis with more than 25 years of experience in the biopharma industry, primarily in senior executive roles, and will be based in the U.S. following the establishment of Versantis, Inc. He succeeds co-founder Dr. Vincent Forster, who will assume the role
NEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Mark J. Fitzpatrick to its board of directors. “Mark is an experienced industry executive, who has led financial strategy at biopharmaceutical companies across all stages of development,” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. “His extensive experience working with late-stage, rare disease companies will be particular
ALLN-346, an orally administered enzyme in development for the treatment of hyperuricemia and gout, demonstrates a statistically significant reduction in serum uric acid and a well-tolerated safety profile in first cohort of patients with hyperuricemia and chronic kidney disease in the Phase 2a Study 201 Allena to host webinar to discuss the initial Study 201 data with Key Opinion Leaders Robert Terkeltaub, M.D. and David S. Goldfarb, M.D. today at 8:00 am ET; log-in information belowALLN-346 Phase 2a Study 202 is actively enrolling patients with gout and stages 2 and 3 chronic kidney disease in parallel cohorts; data from both cohorts expected in Q1 2022Company currently evaluating potenti
NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 10,400,000 shares of common stock of the Company, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, 2020, subject to satisfact
NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 8,000,000 shares of common stock of the Company, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, 2020, subject to sa
SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)
SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)
SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)
Gainers Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) jumped 64% to $0.1199. Allena Pharmaceuticals shares dipped over 30% on Tuesday after the company announced it has filed for bankruptcy. Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) shares surged 44.3% to $4.7893 after Alliance Global Partners initiated coverage on the stock with a Buy rating and a $20 price target. IMARA Inc. (NASDAQ:IMRA) rose 37% to $1.57 after the company announced it entered into an asset purchase agreement with Cardurion Pharmaceuticals to sell tovinontrine and other assets of its PDE9 program for $34.75 million upfront. Sidus Space, Inc. (NASDAQ:SIDU) gained 26.7% to $3.3701 after the company announced that it has
Gainers BioVie (NASDAQ:BIVI) stock increased by 32.3% to $4.55 during Wednesday's pre-market session. The company's market cap stands at $130.2 million. bioAffinity Technologies (NASDAQ:BIAF) shares increased by 30.61% to $7.04. The market value of their outstanding shares is at $19.2 million. Imara (NASDAQ:IMRA) stock moved upwards by 23.93% to $1.45. The market value of their outstanding shares is at $38.1 million. Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 18.37% to $3.93. The market value of their outstanding shares is at $18.8 million. Spero Therapeutics (NASDAQ:SPRO) shares increased by 17.69% to $1.33. The company's market cap stands at $46.6 million. iSpeci